|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
ACE2 is an integral membrane protein that degrades angiotensin II and has an emerging role as a circulating biomarker of cardiovascular disease.
|
31607667 |
2020 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
<b>Abbreviations</b>: Angiotensin-converting enzyme (ACE); Angiotensin converting enzyme inhibitors (ACEIs); Angiotensin II (ANG II); Analysis of variance (ANOVA); Angiotensin receptor blockers (ARBs); Blood Pressure (BP); Calcium Antagonists Calcium Channel Blockers (CCB); Chronic kidney diseases (CKD); Sodium carboxyl methyl cellulose (CMC-Na); Cardiac mass index (CMI); Cardiovascular diseases (CVD); Diastolic blood pressure (DBP); Enzyme-linked immunosorbent assay (ELISA); Hematoxylin-eosin (H&E); Kidney mass index (KMI); Liver mass index (LMI); Mean arterial blood pressure (MAP); Plasma renin concentration (PRC); Renin-angiotensin system (RAS); Rennin (REN); Systolic blood pressure (SBP); Student-Newman-Keuls q test (SNK-q test); Spontaneous hypertension rats (SHR); Valsartan asleep Administration (VSA); Valsartan awake Administration (VWA); Wistar-Kyoto (WKY); Mesor (M); Amplitude (A); Phase (φ).
|
31096810 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensinogen (AGT) M235T gene polymorphism is associated with risk of ischemic stroke and cardiovascular disease.
|
30409744 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin II (AngII) and the mineralocorticoid receptor (MR) ligand aldosterone both contribute to cardiovascular disorders, including hypertension and adverse vascular remodeling.
|
31373631 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Blockers of G-protein coupled receptors (GPCRs), angiotensin II (Ang II) type 1 (AT<sub>1</sub>) receptor and β<sub>1</sub>-adrenergic (Ad) receptor, have been shown to improve the prognosis of cardiovascular disease.
|
31079923 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The angiotensin II AT<sub>1</sub> and the endothelin 1 ET<sub>A</sub> receptors play a crucial role in the pathogenesis of cardiovascular diseases like hypertension, heart failure, stroke, pulmonary hypertension, and cardiac hypertrophy.
|
30851407 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The results of a genome-wide association study (GWAS) showed that two functional single-nucleotide polymorphisms (SNPs; rs699A>G and rs5050T>G) in the angiotensinogen (AGT) gene were related to cardiovascular disease susceptibility.
|
30719178 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The objective of this study is to investigate the effect of metformin on angiotensin II (Ang II)-induced hypertension and cardiovascular diseases.
|
30664704 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
So, the aim of current study was to develop efficient low-cost method for genotyping of cardiovascular disease and hypertension associated polymorphisms of AGT (rs4762, rs5051) and CYP11B1 (rs6410).
|
30478747 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin II (Ang II) modulates VSMCs phenotypic switch that play a critical role in the cardiovascular diseases.
|
30654940 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Since more than three decades suppression of AngII generation by inhibition of the angiotensin-converting enzyme (ACE) or blockade of the AngII-receptor has shown clinical benefit by reducing hypertension, atherosclerosis and other inflammation-associated cardiovascular diseases.
|
29244531 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Increased chymase-dependent angiotensin II generation has been reported in several cardiovascular diseases, including atherosclerosis and aneurysmal lesions.
|
30518985 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin II (Ang II)-induced damage to endothelial cells (ECs) plays a crucial role in the pathogenesis of cardiovascular disease.
|
30838022 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin II (Ang II) is involved in the pathogenic progress of cardiovascular diseases via the promotion of abnormal proliferation and migration of human vascular smooth muscle cells (HVSMCs).
|
30662355 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin II (Ang II) is reported to be involved in the development of various cardiovascular diseases by disrupting microvessel permeability, however, the underlying mechanism remains to be elucidated.
|
29749551 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
It highlights the potential role of pro-inflammatory cytokines, leucocytes and angiotensin II in disrupting the blood-brain barrier in cardiovascular diseases.
|
28986948 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin II (Ang II) is implicated in the development of cardiovascular disorders including hypertension and atherosclerosis.
|
29609002 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Excessive activation of AT1R by angiotensin II (Ang II) leads to cardiovascular disease and may be involved in the development of insulin resistance and diabetes.
|
29136335 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Circulating angiotensin-(1-7) was diminished whereas urinary angiotensin-(1-7) was increased relative to angiotensin II in adolescents born preterm, suggesting prematurity may increase the risk of cardiovascular disease by altering the renin-angiotensin system.
|
29846325 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin II (Ang-II), a vascular stimulant associated with cardiovascular disease progression, has been demonstrated to be mainly involved in cardiovascular remodeling of atherosclerosis and cardiac hypertrophy.
|
29369845 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Several antagonists of GPCRs, such as βARs (β-adrenergic receptors) and Ang II (angiotensin II) receptors, are now considered standard of therapy for a wide range of cardiovascular disease, such as hypertension, coronary artery disease, and heart failure.
|
30355236 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
As a member of the renin-angiotensin system (RAS), the PRR has demonstrated to be of relevance in cardiovascular diseases (CVD) because it can activate prorenin and enhance the enzymatic activity of renin, thus promoting angiotensin II formation.
|
29101170 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Current evidence is insufficient to show differences in any members within the angiotensin II receptor blocker drug class with respect to blood pressuring lowering effects or a reduction in cardiovascular diseases.
|
28807582 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Effects of toll-like receptor 4 (TLR4)/nuclear factor-κB (NF-κB) pathway on expression of angiotensinogen and AT<sub>1a</sub> receptor were investigated, to explore the role of TLR4/NF-κB signaling pathway in cardiovascular disease.
|
30344664 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin II (Ang II)-mediated hypertension is a major risk factor for cardiovascular diseases.
|
30036880 |
2018 |